Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension

Authors
Kim, WoohyeunChang, KiyukCho, Eun JooAhn, Jeong-CheonYu, Cheol WoongCho, Kyoung-ImKim, Yong-JinKang, Duk-HyunKim, Seok-YeonLee, Sang-HakKim, UngKim, Shin-JaeAhn, Young KeunLee, Chang HoonShin, Jin HoKim, MikyungPark, Chang Gyu
Issue Date
2월-2020
Publisher
WILEY
Keywords
amlodipine; dyslipidemia; hypertension; rosuvastatin; single-pill combination
Citation
JOURNAL OF CLINICAL HYPERTENSION, v.22, no.2, pp.261 - 269
Indexed
SCIE
SCOPUS
Journal Title
JOURNAL OF CLINICAL HYPERTENSION
Volume
22
Number
2
Start Page
261
End Page
269
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/57787
DOI
10.1111/jch.13774
ISSN
1524-6175
Abstract
This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia. A total of 106 patients of 15 institutions in Korea were randomly assigned to 1 of 3 treatment groups: rosuvastatin 20 mg + amlodipine 10 mg, amlodipine 10 mg, or rosuvastatin 20 mg. After 8 weeks of treatment, the mean +/- SD of change in mean sitting systolic blood pressure (msSBP) was -22.82 +/- 12.99 mm Hg in the rosuvastatin + amlodipine group, the most decreased among the treatment groups. The percentage of patients whose msSBP decreased >= 20 mm Hg or msDBP decreased >= 10 mm Hg was also highest in this group (74.29%). The mean +/- SD percentage change in low-density lipoprotein cholesterol (LDL-C) level from baseline after 8 weeks was -52.53% +/- 11.21% in the rosuvastatin + amlodipine group, the most decreased among the treatment groups. More patients in the rosuvastatin + amlodipine group achieved their target LDL-C goal at 8 weeks, compared with the other treatment groups (97.14%). No serious adverse events or adverse drug reactions were observed in all groups. In hypertensive patients with dyslipidemia, combination treatment with rosuvastatin 20 mg + amlodipine 10 mg effectively reduced blood pressure and LDL-C levels while maintaining safety.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Ahn, Jeong Cheon photo

Ahn, Jeong Cheon
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE